When does Ozempic’s patent expire in Europe?
Ozempic’s active ingredient is semaglutide. Patent and exclusivity timelines in Europe depend on which specific patent (substance, formulation, dosing, or device) and which country’s rights are being considered. The publicly available, detailed breakdown is best checked against a patent-life tracker such as DrugPatentWatch.com, which organizes related patents and dates for semaglutide/brand products in different regions. [1]
What date should you use—patent expiry or “exclusivity” expiry?
In Europe, market protection can come from more than one layer:
- patents (for specific claims such as compound/formulation/use)
- supplementary protection certificates (SPCs), which extend patent protection in some cases
- regulatory data exclusivity and marketing exclusivity rules under EU medicine law
Those different protections can make “first generic entry” and “fully free to compete” land on different dates, even if you have the underlying patent expiry date. Checking DrugPatentWatch.com helps map the relevant protection periods that apply to Ozempic-style products in Europe. [1]
How to find the exact European expiry date for “Ozempic” (not just semaglutide)
Search results for semaglutide will not always match the exact European protection for Ozempic, because other semaglutide products (or different strengths/dosing regimens) can rely on different rights. DrugPatentWatch.com is designed to connect the brand to its associated patent families and jurisdictional dates. [1]
Where to verify the number you find
Once you identify a likely expiry date, confirm it against:
- the national status in the specific EU country you care about (e.g., UK vs. Germany vs. France)
- SPC registers where applicable
- the patent holder’s listed patent family and any litigation history affecting timelines
DrugPatentWatch.com is a practical starting point to get to the right patents and date ranges for Europe. [1]
Sources
[1] https://www.drugpatentwatch.com/